- Home
- LESL vs OCS Comparison
LESL vs OCS Comparison
Compare LESL & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LESL
- OCS
- Stock Information
- Founded
- LESL 1963
- OCS 2003
- Country
- LESL United States
- OCS Switzerland
- Employees
- LESL N/A
- OCS N/A
- Industry
- LESL Diversified Commercial Services
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- LESL Miscellaneous
- OCS Health Care
- Exchange
- LESL Nasdaq
- OCS Nasdaq
- Market Cap
- LESL 538.1M
- OCS 711.4M
- IPO Year
- LESL 2020
- OCS N/A
- Fundamental
- Price
- LESL $2.20
- OCS $22.44
- Analyst Decision
- LESL Hold
- OCS Strong Buy
- Analyst Count
- LESL 8
- OCS 5
- Target Price
- LESL $3.96
- OCS $28.80
- AVG Volume (30 Days)
- LESL 5.2M
- OCS 90.4K
- Earning Date
- LESL 01-30-2025
- OCS 11-07-2024
- Dividend Yield
- LESL N/A
- OCS N/A
- EPS Growth
- LESL N/A
- OCS N/A
- EPS
- LESL N/A
- OCS N/A
- Revenue
- LESL $1,330,121,000.00
- OCS $1,027,571.00
- Revenue This Year
- LESL $4.50
- OCS $6.21
- Revenue Next Year
- LESL $4.10
- OCS $760.04
- P/E Ratio
- LESL N/A
- OCS N/A
- Revenue Growth
- LESL N/A
- OCS N/A
- 52 Week Low
- LESL $2.02
- OCS $10.55
- 52 Week High
- LESL $8.21
- OCS $23.08
- Technical
- Relative Strength Index (RSI)
- LESL 43.88
- OCS 89.35
- Support Level
- LESL $2.13
- OCS $16.90
- Resistance Level
- LESL $2.27
- OCS $23.08
- Average True Range (ATR)
- LESL 0.12
- OCS 0.52
- MACD
- LESL 0.02
- OCS 0.54
- Stochastic Oscillator
- LESL 44.26
- OCS 89.89
About LESL Leslie's Inc.
Leslies Inc is a direct-to-consumer pool and spa care brand offering a comprehensive assortment of products across chemicals, equipment and parts, cleaning and maintenance equipment, and safety, recreational, and fitness-related products. The company offers its products and services for Residential Pool, Residential Spa, Professional Pool, and Commercial Pool consumers. Geographically, it operates only in the United States.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.